Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.84 |
| ▸ | MAPT | P10636 | 7/20 | 0.85 |
| ▸ | LMNA | P02545 | 7/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 3/20 | 0.85 |
| ▸ | GMNN | O75496 | 3/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.85 |
| ▸ | GAA | P10253 | 2/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.84 |
| ▸ | HTR2A | P28223 | 5/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.84 |
| ▸ | HRH1 | P35367 | 5/20 | 0.84 |
| ▸ | DRD3 | P35462 | 5/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL871708 | 1.00 | MAPT (0.85) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL30583942 | 1.00 | MAPT (0.85) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL5494383 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40756 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29634451 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL1806022 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL718254 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40755 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL8911628 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29686418 | 0.92 | LMNA (1.00) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384770-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-12 | — | — | US | disclosed |
| CN-116209446-B | 7- (Piperidin-1-yl) -4H-pyrimido [1,2-B ] pyridazin-4-one derivatives as positive allosteric modulators of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2025-05-13 | — | — | CN | disclosed |
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240343721-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | US | disclosed |
| US-12084436-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-10 | — | — | US | disclosed |
| US-11958845-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| CN-114588124-B | Delayed release pharmaceutical composition | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6328979-B1 | Sustained release medicinal compositions | YAMANOUCHI PHARMACEUTICALS, CO. LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1043030-A1 | SUSTAINED RELEASE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043031-A1 | SUSTAINED RELEASE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5830497-A | Medicated plaster containing basic physiologically active agents and/or salts thereof | NITTO DENKO CORPORATION (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-4540602-A | Process for the preparation of activated pharmaceutical compositions | FREUND INDUSTRY COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084436-B2 | Heterocyclic compound | HDAC1, HDAC5, HDAC6 | DRD2 3691/4885MAPT 72/4885LMNA 2022/4885 |
| US-20240343721-A1 | HETEROCYCLIC COMPOUND | HDAC6, HDAC1, HDAC5 | DRD2 3705/4885MAPT 19/4885LMNA 3611/4885 |
| US-11958845-B2 | Heterocyclic compound | HDAC6, HDAC1, HDAC5 | DRD2 3705/4885MAPT 19/4885LMNA 3611/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | DRD2 2788/4885MAPT 2013/4885LMNA 4543/4885 |
| US-12384770-B2 | Heterocyclic compound | HDAC6, HDAC1, HDAC5 | DRD2 3705/4885MAPT 19/4885LMNA 3611/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | DRD2 4349/4885MAPT 2229/4885LMNA 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.